Live feed07:00:00·1155dPRReleasevia QuantisnowMorphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory MeasuresByQuantisnow·Wall Street's wire, on your screen.MORF· Morphic Holding Inc.Health Care
